Saturday, 14 February 2015 10:23

Anticoagulation news items. Week commencing 9th February 2015

Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial

The Lancet Neurology

Pilot study data (n=250) found no difference in efficacy of antiplatelet and anticoagulant drugs at preventing stroke and death in patients with symptomatic carotid and vertebral artery dissection. However, stroke events were rare in both groups.


Medicines Evidence Commentary: Medicines optimisation: identifying medicines associated with serious medication errors

National Institute for Health and Care Excellence

Discussion of a systematic review which has identified those medicines reported in the literature that most commonly cause serious adverse reactions because of medication errors.


EMA receives marketing authorisation application for eltrombopag to include children with chronic immune (idiopathic) thrombocytopenic purpura

Biospace Inc.

A variation in Marketing Authorisation has been submitted to the EMA for the use of eltrombopag (Revolade) for the treatment of children >1 year with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids or immunoglobulins.




The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: